Investors of ImmunityBio, Inc. Have Chance to Lead Securities Fraud Lawsuit

ImmunityBio Securities Fraud Lawsuit Opportunity

In a significant development for investors of ImmunityBio, Inc. (NASDAQ: IBRX), The Rosen Law Firm has announced an opportunity for those who purchased securities between January 19, 2026, and March 24, 2026, to lead a class action lawsuit against the company. This lawsuit arises out of allegations of securities fraud, and those interested must act quickly, as the deadline to apply as lead plaintiff is set for May 26, 2026.

Background of the Case

The Rosen Law Firm specializes in representing investor rights globally and has initiated this securities class action due to serious concerns regarding the accuracy of ImmunityBio's public communications during the specified class period. It has been alleged that prominent statements made by company officials, including Patrick Soon-Shiong, were misleading about the capabilities of their drug, Anktiva. These misleading claims have purportedly caused investors to suffer financial losses when the truth became known, leading to the substantial damages apparent in the stock’s performance.

What Investors Should Know

Investors who purchased shares of ImmunityBio during the aforementioned class period may be eligible for compensation without having to pay upfront legal fees. The Rosen Law Firm operates on a contingency fee basis, meaning that fees will only be collected if the case results in a recovery. This approach ensures that every investor has access to legal recourse irrespective of their financial circumstances.

How to Join the Class Action

For those interested in participating, joining the class action lawsuit is straightforward. Interested individuals can fill out a submission form on Rosen Law Firm's website or contact Phillip Kim, Esq., directly through a toll-free number or via email. It’s crucial for those wishing to become the lead plaintiff to submit their motions to the court by the deadline, cementing their position as a representative for the class.

Important Information and Decisions

While many investors may be considering their legal options, it is essential to remember that the class has not yet been certified. This means that unless an investor actively retains a counsel their involvement in the lawsuit may not be guaranteed at this stage. Investors are encouraged to choose qualified legal representation carefully, as many firms claim expertise in such cases but may not have the experience demonstrated by The Rosen Law Firm, which has managed substantial settlements in similar lawsuits.

The Firm's Track Record

The Rosen Law Firm stands out with a distinguished history of representing investors in securities class actions, boasting the largest settlements ever achieved against companies based in China. Their expertise has been recognized consistently, ranking them highly among peers for their effectiveness in recovering funds for defrauded investors. Notably, they secured over $438 million for their clients in 2019 alone, underscoring their capability to handle complex lawsuits effectively.

Next Steps for Investors

To ensure potential recovery, investors are urged to act quickly and gather all necessary information regarding their purchases of ImmunityBio securities. Joining the lawsuit not only allows them to possibly recover losses but also helps hold companies accountable for their actions, contributing to the integrity of the market.

For ongoing updates and legal developments regarding this situation, investors can follow The Rosen Law Firm’s social media accounts on platforms such as LinkedIn and Twitter.

In conclusion, the opportunity for ImmunityBio, Inc.’s investors to participate in this class action lawsuit represents a critical moment for those seeking justice and compensation for their financial losses. Quick action may provide a pathway to recovery and accountability in a challenging investment landscape.